

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/221945 A9

(43) International Publication Date
23 November 2023 (23.11.2023)

(51) International Patent Classification:

A61K 31/12 (2006.01) A61P 35/00 (2006.01)
A61K 47/00 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/CN2023/094352

(48) Date of publication of this corrected version:

11 January 2024 (11.01.2024)

(22) International Filing Date:

15 May 2023 (15.05.2023)

(15) Information about Correction:

see Notice of 11 January 2024 (11.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/342,284 16 May 2022 (16.05.2022) US

(71) Applicant: CALIWAY BIOPHARMACEUTICALS

CO., LTD. [CN/CN]; 32F.-9, No. 99, Sec. 1, Xintai 5th Rd.,
Xizhi Dist., New Taipei City, Taiwan 221 (CN).

(72) Inventor: LING, Yu-Fang; 32F.-9, No. 99, Sec. 1, Xintai

5th Rd., Xizhi Dist., New Taipei City, Taiwan 221 (CN).

(74) Agent: LUNG TIN INTELLECTUAL PROPERTY

AGENT LTD.; 18th Floor, Tower B, Grand Place No. 5
Huizhong Road, Chaoyang District, Beijing 100101 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR ALLEVIATING CONDITIONS CAUSED BY ABNORMAL SUBCUTANEOUS DEPOSIT OF ADIPOSE TISSUE OR FAT

(57) Abstract: Methods for alleviating a condition caused by abnormal subcutaneous deposit of adipose tissue or fat in a subject in need thereof an effective amount of a composition comprising a first active agent, which comprises (i) a resveratrol compound, a curcumin compound, a quercetin compound, a puerarin compound, or a combination thereof, and (ii) a pharmaceutically acceptable carrier.

WO 2023/221945 A9